Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

GLPG-1205 demonstrates good safety in a phase I study

Oct. 21, 2014

CK18 as a potential predictor of type 2 diabetes in patients with NAFLD

Oct. 21, 2014

Cystic fibrosis candidate N-6022 well tolerated in phase I study

Oct. 21, 2014

HMB-45 staining increases after UVB treatment for vitiligo

Oct. 21, 2014

Results from the first study of fidaxomicin in pediatric patients with CDAD

Oct. 21, 2014

Interim analysis of PUNCH-CD trial results demonstrate safety and efficacy of RBX-2660

Oct. 20, 2014

Results from PIONEER II trial of adalimumab in the treatment of hidradenitis suppurativa

Oct. 20, 2014

Phase I results for the new prolonged-duration local anesthetic, neosaxitoxin

Oct. 20, 2014

Phase II cystic fibrosis candidate NVP-QBW-251 data reported

Oct. 20, 2014

Serotonin receptor polymorphisms studied in patients with refractory depression

Oct. 20, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...